EPIPEN JR. Drug Patent Profile

When do Epipen Jr. patents expire, and when can generic versions of Epipen Jr. launch?

Epipen Jr. is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in EPIPEN JR. is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epipen Jr.

A generic version of EPIPEN JR. was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for EPIPEN JR.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	6
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	15
Patent Applications:	4,181
DailyMed Link:	EPIPEN JR. at DailyMed

Recent Clinical Trials for EPIPEN JR.

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Washington University School of Medicine	PHASE1
Insignis Therapeutics, Inc.	PHASE1
Novotech (Australia) Pty Limited	PHASE1

See all EPIPEN JR. clinical trials

Pharmacology for EPIPEN JR.

Drug Class	Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists

Paragraph IV (Patent) Challenges for EPIPEN JR.

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIPEN JR.	Injection (Auto- injector)	epinephrine	0.15 mg/0.3 mL and 0.3 mg/0.3 mL	019430	1	2009-07-20

US Patents and Regulatory Information for EPIPEN JR.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	EPIPEN JR.	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-002	Dec 22, 1987	AB	RX	Yes	Yes

Expired US Patents for EPIPEN JR.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	EPIPEN JR.	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-002	Dec 22, 1987	7,449,012
Viatris	EPIPEN JR.	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-002	Dec 22, 1987	7,794,432
Viatris	EPIPEN JR.	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-002	Dec 22, 1987	9,586,010
Viatris	EPIPEN JR.	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-002	Dec 22, 1987	8,870,827
Viatris	EPIPEN JR.	epinephrine	INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS	019430-002	Dec 22, 1987	8,048,035

International Patents for EPIPEN JR.

See the table below for patents covering EPIPEN JR. around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	2179759
World Intellectual Property Organization (WIPO)	2006017732
Portugal	2179759
Denmark	2204201
Japan	4362143
Spain	2792185
Canada	2576776	INJECTEUR AUTOMATIQUE (AUTOMATIC INJECTOR)

Supplementary Protection Certificates for EPIPEN JR.

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	2025C/508	Belgium		PRODUCT NAME: COMBINATIE VAN EPINEPHRINE EN DODECYLMALTOSIDE, IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20240823

Market Dynamics and Financial Trajectory for EPIPEN JR.

Last updated: February 19, 2026

What is the current market size and growth trajectory for epinephrine auto-injectors?

The global epinephrine auto-injector market was valued at approximately USD 2.9 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2023 to 2030, reaching USD 6.3 billion.

Key drivers include increasing prevalence of severe allergic reactions, rising awareness among parents and healthcare providers, and expanding distribution in emerging markets. North America dominates the market, accounting for roughly 50% of sales in 2022, driven by FDA regulatory approvals and high awareness levels. Europe follows, with a 25% share, supported by national allergy management programs. The Asia-Pacific region shows rapid growth potential, with a CAGR of 12%, as awareness rises and disposable income increases.

How do regulatory policies impact sales and development?

The U.S. Food and Drug Administration (FDA) approved the first generic epinephrine auto-injector in 2018, following the original EpiPen’s patent expiration in 2017. Multiple generic versions have entered the market, intensifying competition and reducing prices. The FDA’s requirement for child-appropriate formulations influenced product development, leading to the launch of EpiPen Jr. in 2016.

New regulatory pathways, such as the 505(b)(2) application route, streamline approval of modified formulations, encouraging innovation. Regulatory vigilance around device safety and administration instructions remains high, affecting product recalls and modifications.

European Medicines Agency (EMA) approvals mirror U.S. trends, with generics and substitutes increasing availability across Europe. Stringent national regulations, especially concerning manufacturing standards and labeling, influence market entry and pricing strategies.

What are the competitive landscape and product innovation trends?

The market is characterized by several key players:

• Mylan (subsidiary of Viatris), with the EpiPen brand.
• Kaléo Inc., with Auvi-Q, the only alternative auto-injector with voice-guided instructions.
• Teva Pharmaceuticals, offering generic epinephrine auto-injectors.

Market competition has shifted toward price reductions, with generic options costing approximately 40-60% less than the EpiPen brand. This has led to increased accessibility, especially in institutional and public settings.

Product innovations include:

• Smaller, more portable devices.
• Pre-filled, ready-to-use formats.
• Devices with improved needle safety features.
• Digital integration for dosage tracking in development.

Such innovations target improving ease of administration, safety, and compliance with treatment guidelines.

How does insurance coverage influence market penetration?

Insurance coverage remains a key factor limiting or enabling access:

• In the U.S., insurance plans often cover EpiPen and its generics, but copayments can range from USD 25 to USD 100 per device.
• The introduction of low-cost generics has expanded coverage options and reduced out-of-pocket costs.

Some insurers impose prior authorization requirements to control expenditures, which affects timely access, especially in schools and public institutions. Medicaid and federal programs have negotiated discounts and preferred formulary placements, influencing sales volume.

What is the financial outlook for EpiPen Jr. specifically?

EpiPen Jr. accounts for approximately 75% of the epinephrine auto-injector market revenue, valued at about USD 2.1 billion in 2022. Its revenue is projected to grow at a CAGR of 9.8% through 2030, based on increasing allergy prevalence, particularly peanut allergies, and enhanced awareness.

Pricing strategies for EpiPen Jr. have involved direct discounts and rebate arrangements, preserving market share amid heightened competition. The product’s stability in formulations and ongoing safety improvements sustain its market position.

Key factors impacting future revenue streams

• Patent expirations of originator products and increased generic competition.
• Innovation in device design and user safety features.
• Regulatory landscape shifts, especially around affordability policies and device approval pathways.
• Marketing and patient education programs to increase awareness and administration compliance.
• Expansion into emerging markets with high allergy prevalence and improving healthcare infrastructure.

Summary of market valuation and growth forecasts

Year	Market Size (USD billion)	CAGR	Notes
2022	2.9	-	Baseline year
2025	4.0	10.5%	Projected growth
2030	6.3	-	Market size estimate

Key Takeaways

• The global epinephrine auto-injector market exhibits steady growth, driven by allergy prevalence and increased awareness.
• Price competition from generics has reduced premiums but expanded access.
• Innovations focus on device safety, portability, and digital features.
• Regulatory policies influence product approvals, safety standards, and market entry.
• Insurance coverage significantly impacts adoption rates across regions.

FAQs

1. What factors are most influencing the growth of the EPIPEN Jr. market?
   Rising allergy prevalence, better awareness, regulatory approvals of generics, and pricing strategies are primary factors.

2. How have patent expirations affected the competitive landscape?
   Patent expirations in 2017 led to multiple generic products, lowering prices and increasing market penetration.

3. What innovations are expected in future EpiPen Jr. products?
   Device safety features, digital dose tracking, and miniaturization are areas of ongoing development.

4. What regulatory challenges could impact EPIPEN Jr. sales?
   Changes in affordability policies, safety standards, and approval pathways could affect development and pricing strategies.

5. How significant is the emerging markets’ role in future growth?
   They present rapid growth potential due to increasing allergy incidence and improving healthcare access, with CAGR exceeding 10%.

Sources:

[1] MarketWatch (2023). Epinephrine auto-injector market analysis.

[2] Grand View Research (2023). Auto-injectors market size and forecast.

[3] FDA (2018). Approval of generic epinephrine auto-injectors.

[4] European Medicines Agency (2022). Market guidance on epinephrine devices.